Transplantation of Human Chorion-Derived Cholinergic Progenitor Cells: A Novel Treatment for Neurological Disorders Publisher Pubmed



Mohammadi A¹ ; Malekijamshid A^{2, 3, 4} ; Sanooghi D⁵ ; Milan PB^{3, 6} ; Rahmani A^{3, 7} ; Sefat F⁸ ; Shahpasand K⁹ ; Soleimani M^{2, 3} ; Bakhtiari M^{2, 3} ; Belali R¹⁰ ; Faghihi F³ ; Joghataei MT^{2, 3, 4} ; Perry G¹¹ ; Mozafari M^{3, 6, 12}
Source: Molecular Neurobiology Published:2019

Abstract

A neurological disorder is any disorder or abnormality in the nervous system. Among different neurological disorders, Alzheimer’s disease (AD) is recognized as the sixth leading cause of death globally. Considerable research has been conducted to find pioneer treatments for this devastating disorder among which cell therapy has attracted remarkable attentions over the last decade. Up to now, targeted differentiation into specific desirable cell types has remained a major obstacle to clinical application of cell therapy. Also, potential risks including uncontrolled growth of stem cells could be disastrous. In our novel protocol, we used basal forebrain cholinergic progenitor cells (BFCN) derived from human chorion-derived mesenchymal stem cells (hC-MSCs) which made it possible to obtain high-quality population of cholinergic neurons and in vivo in much shorter time period than previous established methods. Remarkably, the transplanted progenitors fully differentiated to cholinergic neurons which in turn integrated in higher cortical networks of host brains, resulting in significant improvement in cognitive assessments. This method may have profound implications in cell therapies for any other neurodegenerative disorders. [Figure not available: see fulltext.] © 2018, Springer Science+Business Media, LLC, part of Springer Nature.